Malfertheiner Peter, Megraud Francis, Rokkas Theodore, Gisbert Javier P, Liou Jyh-Ming, Schulz Christian, Gasbarrini Antonio, Hunt Richard H, Leja Marcis, O'Morain Colm, Rugge Massimo, Suerbaum Sebastian, Tilg Herbert, Sugano Kentaro, El-Omar Emad M
Medical Department 2, LMU, Munchen, Germany
Department of Radiology, LMU, Munchen, Germany.
Gut. 2022 Aug 8. doi: 10.1136/gutjnl-2022-327745.
Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with gastritis, specific issues persist and require regular updates for optimised management.The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of and antibiotic therapies and their impact on the gut microbiota are also considered.Progress made in the management of infection is covered in the present sixth edition of the Maastricht/Florence 2021 Consensus Report, key aspects related to the clinical role of infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of infection in various clinical fields.
感染被正式认定为一种传染病，这一实体现已被纳入《国际疾病分类》第11次修订版。原则上，这导致了所有感染患者都应接受治疗的建议。在与胃炎相关的广泛临床范围内，特定问题依然存在，需要定期更新以实现优化管理。文中讨论了不同临床情况的识别、恰当检测以及预防胃癌和其他并发症的有效策略的采用。治疗面临着抗生素耐药性不断上升的挑战，需要考虑采用新型分子技术进行药敏试验，并谨慎选择一线和挽救性治疗方案。文中还考虑了幽门螺杆菌和抗生素疗法的作用及其对肠道微生物群的影响。《马斯特里赫特/佛罗伦萨2021年共识报告》第六版涵盖了幽门螺杆菌感染管理方面取得的进展，对与幽门螺杆菌感染临床作用相关的关键方面进行了重新评估和更新。来自29个国家的41位专家代表全球群体，在五个工作组中审查了与幽门螺杆菌感染相关的新数据：（1）适应证/关联，（2）诊断，（3）治疗，（4）预防/胃癌，以及（5）幽门螺杆菌与肠道微生物群。各工作组的结果进行了展示，供包括所有参与者在内的最终共识投票。基于现有最佳证据以及与不同临床领域幽门螺杆菌感染管理的相关性，给出了相关建议。
